Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

The year-over-year increase in revenues was driven by higher Diabetes and Obesity Care sales as GLP-1 product sales ... with the industry’s 3.1% decline. Image Source: Zacks Investment Research ...

Hims & Hers’ decision to advertise at the Super Bowl represents an ambitious play for the brand as it positions itself in the ...

GLP-1 drugs are also engineered peptides, which are expensive to manufacture. Metsera has technologies and drug candidates intended ... the Nasdaq Friday under the stock symbol “MTSR.” ...